• Berrino F. & the EUROCARE Working Group (2003) Survival of cancer patients in Europe: the EUROCARE-3 Study. Annals of Oncology 14 (Suppl. 5), v9v13.
  • Clemons M.J., Dranitsaris G., Ooi W.S., Yogendran G., Sukovic T., Wong B.Y., Verma S., Pritchard K.I., Trudeau M. & Cole D.E. (2006) Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. Journal of Clinical Oncology 24, 48954900.
  • Coleman R.E. (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treatment Reviews 27, 165176.
  • Coleman R.E. (2004) The role of bisphosphonates in breast cancer. Breast 13 (Suppl. 1), S1928.
  • Coleman R.E. & Rubens R.D. (1987) The clinical course of bone metastases from breast cancer. British Journal of Cancer 55, 6166.
  • Coleman R.E. & Seaman J.J. (2001) The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. Seminars in Oncololgy 28 (Suppl. 6), 1116.
  • Delea T., McKiernan J., Brandman J., Edelsberg J., Sung J., Raut M. & Oster G. (2006) Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. Journal of Support Oncololgy 4, 341347.
  • DePuy V., Anstrom K.J., Castel L.D., Schulman K.A., Weinfurt K.P & Saad F. (2007) Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 15, 869876.
  • Ferlay J., Bray F., Pisani P. & Parkin D.M. (2004) GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0. IARC Press, Lyon, France. Available at:
  • Gatta G. & the EUROCARE Working Group (2003) Cancer survival in European adolescents and young adults. European Journal of Cancer 39, 26002610.
  • Groot M.T., Boeken Kruger C.G.G., Pelger R.C.M. & Uyl-de Groot C.A. (2003) Costs of prostate cancer, metastatic to the bone, in the Netherlands. European Urology 43, 226232.
  • Ito Y. & Tokudome N. (2006) Chemotherapy for metastatic breast cancer [Japanese]. Japanese Journal of Cancer & Chemotherapy 33, 742746.
  • Karamouzis M.V., Ioannidis G. & Rigatos G. (2007) Quality of life in metastatic breast cancer patients under chemotherapy or supportive care: a single-institution comparative study. European Journal of Cancer Care 16, 433438.
  • Lipton A. (2005) Management of bone metastases in breast cancer. Current Treatment Options in Oncology 6, 161171.
  • López G., Pollán M., Aragonese N., Perez Gomez B., Hernandez Barrera V., Lope V. & Suarez B. (2004) Situation of cancer in Spain: incidence. An Sis Sanit Navar 27, 165173.
  • López G., Pollán M., Aragonese N., Perez Gomez B., Hernandez Barrera V., Lope V. & Suarez B. (2005) The Situation of Cancer in Spain. National Center for Epidemiology. Ministry of Health and Consumer Affairs, Madrid. Available at:
  • Lorusso P. (2001) Analysis of skeletal-related events in breast cancer and response to therapy. Seminars in Oncology 28 (Suppl. 11), 2227.
  • McMillan S.C. (1996) The quality of life of patients with cancer receiving hospice care. Oncology Nursing Forum 23, 12211228.
  • Manders K., Van De Poll-Franse L.V., Creemers G.J., Vreugdenhil G., Van Der Sangen M.J., Nieuwenhuijzen G.A., Roumen R.M. & Voogd A.C. (2006) Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer 6, 179.
  • Mundy G.R. (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Reviews Cancer 2, 584593.
  • National Center for Epidemiology (1996) Cancer mortality in Spain. Years 1996–2002. Website of the National Center for Epidemiology, Area Environmental Epidemiology and Cancer. Available at:
  • Wardley A., Davidson N., Barrett-Lee P., Hong A., Mansi J., Dodwell D., Murphy R., Mason T. & Cameron D. (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised crossover study of community vs hospital bisphosphanate administration. British Journal of Cancer 92, 18691876.
  • Weinfurt K.P., Li Y., Castel L.D., Saad F., Timbie J.W., Glendenning G.A. & Schulman K.A. (2005) The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Annals of Oncology 16, 579584.